Universe Pharmaceuticals (UPC) Cash & Current Investments (2020 - 2025)

Universe Pharmaceuticals has disclosed Cash & Current Investments across 6 years of filings, most recently posting $70.2 million for Q3 2025.

• Cash & Current Investments for Q3 2025 came in at $70.2 million, down 99.77% year-over-year; the trailing twelve-month figure through Sep 2025 was $70.2 million (down 99.77% YoY), and the FY2025 annual result was $70.2 million, down 99.77% from the prior year.
• Cash & Current Investments came in at $70.2 million for Q3 2025 at Universe Pharmaceuticals, down from $30.9 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $30.9 billion in Q3 2024 to a low of $11.4 million in Q1 2024.
• The 5-year median for Cash & Current Investments is $49.4 million (2022), against an average of $5.3 billion.
• Across the five-year window, Cash & Current Investments surged 26155.92% in 2022 and sank 99.77% in 2025, its largest moves.
• Universe Pharmaceuticals' Cash & Current Investments stood at $21.8 million in 2021, then soared by 26155.92% to $5.7 billion in 2022, then retreated by 7.65% to $5.3 billion in 2023, then jumped by 484.03% to $30.9 billion in 2024, then tumbled by 99.77% to $70.2 million in 2025.
• The last three Cash & Current Investments figures came in at $70.2 million (Q3 2025), $30.9 billion (Q3 2024), and $11.4 million (Q1 2024), per Business Quant data.